[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100070576":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":15,"responsibleParty":7,"collaborators":7,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":7,"eligibilityCriteria":92,"healthyVolunteers":89,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":7,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":109,"whyStopped":7,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Tegaserod",[13],{"name":5,"affiliation":5,"role":14},"STUDY_DIRECTOR",[16,29,38,47,57,67,77],{"facility":17,"status":7,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"Consultants for Clinical Research of South Florida","Boynton Beach","Florida","33426","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-80.06643,26.52535,{"lat":27,"lon":26},{"facility":30,"status":7,"city":31,"state":19,"zip":32,"country":21,"countryCode":22,"cosmosGeoPoint":33,"geoPoint":37,"contacts":7},"Miami Research Associates","Miami","33173",{"type":24,"coordinates":34},[35,36],-80.19366,25.77427,{"lat":36,"lon":35},{"facility":39,"status":7,"city":40,"state":19,"zip":41,"country":21,"countryCode":22,"cosmosGeoPoint":42,"geoPoint":46,"contacts":7},"University Clinical Research","Pembroke Pines","33024",{"type":24,"coordinates":43},[44,45],-80.22394,26.00315,{"lat":45,"lon":44},{"facility":48,"status":7,"city":49,"state":50,"zip":51,"country":21,"countryCode":22,"cosmosGeoPoint":52,"geoPoint":56,"contacts":7},"Department of Internal Medicine - Wake Forest University School of Medicine","Winston-Salem","North Carolina","27157",{"type":24,"coordinates":53},[54,55],-80.24422,36.09986,{"lat":55,"lon":54},{"facility":58,"status":7,"city":59,"state":60,"zip":61,"country":21,"countryCode":22,"cosmosGeoPoint":62,"geoPoint":66,"contacts":7},"Consultants for Clinical Research","Cincinnati","Ohio","45219",{"type":24,"coordinates":63},[64,65],-84.51439,39.12711,{"lat":65,"lon":64},{"facility":68,"status":7,"city":69,"state":70,"zip":71,"country":21,"countryCode":22,"cosmosGeoPoint":72,"geoPoint":76,"contacts":7},"Metropolitan Research","Fairfax","Virginia","22031",{"type":24,"coordinates":73},[74,75],-77.30637,38.84622,{"lat":75,"lon":74},{"facility":78,"status":7,"city":79,"state":80,"zip":81,"country":21,"countryCode":22,"cosmosGeoPoint":82,"geoPoint":86,"contacts":7},"The Wisconsin Center for Advanced Research","Milwaukee","Wisconsin","53207",{"type":24,"coordinates":83},[84,85],-87.90647,43.0389,{"lat":85,"lon":84},"100070576","phase-3-assessment-of-the-role-of-tegaserod-therapy-in-the-management-of-gastroesophageal-reflux-disease-gerd-symptoms-in-patients-with-incomplete-response-to-proton-pump-inhibitors-ppis-100070576",false,"NCT00171483","Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).","Inclusion Criteria:\n\n* Heartburn for at least 3 days in the week prior to screening\n* Regurgitation for at least 3 days in the week prior to screening\n* Stable dose PPI therapy \\> 4 weeks\n* Incomplete relief on daily PPI therapy \\> 4 weeks\n\nExclusion Criteria:\n\n* Evidence of structural abnormality of the gastrointestinal tract or disease\u002Fconditions\n* Previous gastrointestinal surgery that may influence esophageal motor function\n* Evidence of cathartic colon or a history of laxative use\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","70 Years",{"count":97,"type":7},30,"INTERVENTIONAL",[100],"PHASE3","Study to assess the effects of tegaserod added to PPI therapy in the resolution of heartburn and regurgitation in patients with incomplete relief from PPIs .",[103],"Gastroesophageal Reflux Disease (GERD)",[105,106,107,108],"GERD","PPI","heartburn","regurgitation","COMPLETED","2008-01-24",{"date":112,"type":113},"2008-01-28","ESTIMATED",{"date":115,"type":7},"2004-01",{"date":117,"type":118},"2005-04","ACTUAL",{"name":5,"class":6},7]